Farxiga is owned by Astrazeneca Ab.
Farxiga contains Dapagliflozin.
Farxiga has a total of 16 drug patents out of which 0 drug patents have expired.
Farxiga was authorised for market use on 08 January, 2014.
Farxiga is available in tablet;oral dosage forms.
Farxiga can be used as treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus, reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes, treatment of type 2 diabetes mellitus; treatment of type 2 diabetes mellitus in combination with exenatide, reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4, treatment of type 2 diabetes mellitus in combination with exenatide, treatment of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
The generics of Farxiga are possible to be released after 09 March, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 years from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months from now) | |
US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(5 years from now) | |
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(6 years from now) | |
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(7 years from now) | |
US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Feb 22, 2022 |
New Indication (I) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic